Relationship of TIMI Myocardial Perfusion Grade to Mortality After Administration of Thrombolytic Drugs
C. Michael Gibson(Baim Institute for Clinical Research), Eugene Braunwald(Mass General Brigham), Frans Van de Werf(KU Leuven), Rebecca Mesley(KU Leuven), Susan J. Marble(KU Leuven), Sabina A. Murphy(Brigham and Women's Hospital), Carolyn H. McCabe(Brigham and Women's Hospital), Kathryn A. Ryan(KU Leuven), Christopher P. Cannon(Brigham and Women's Hospital)
Cited by 856
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k